We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

48 hedge funds and large institutions have $278M invested in KalVista Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

733% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 3

442% more capital invested

Capital invested by funds: $51.3M → $278M (+$227M)

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

85% more funds holding

Funds holding: 26 → 48 (+22)

14.63% more ownership

Funds ownership: 58.49% → 73.12% (+15%)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

Holders
48
Holders Change
+22
Holders Change %
+84.62%
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
25
Increased
9
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$14.3M
2
VMI
VHCP Management II
New York
+$10.3M
3
DM
Deerfield Management
New York
+$8.79M
4
BI
BVF Inc
California
+$8.23M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.12M

Top Sellers

Rank Fund Capital Flow
1
SLG
Stanley-Laman Group
Pennsylvania
-$545K
2
TI
Telemetry Investments
New York
-$529K
3
Deutsche Bank
Deutsche Bank
Germany
-$232K
4
DS
DRW Securities
Illinois
-$167K
5
UBS Group
UBS Group
Switzerland
-$33.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$57M – – –
RCM
2
RA Capital Management
Massachusetts
$31.9M – – –
VC
3
Vivo Capital
California
$30.1M +$14.3M +1,058,824 +353%
VMI
4
VHCP Management III
New York
$28.4M +$17.4M +1,284,931 New
EAM
5
Eventide Asset Management
Massachusetts
$19.9M – – –
VMI
6
VHCP Management II
New York
$16.8M +$10.3M +759,181 New
DM
7
Deerfield Management
New York
$14.4M +$8.79M +650,000 New
BI
8
BVF Inc
California
$13.5M +$8.23M +609,014 New
IVM
9
InterWest Venture Management
California
$8.6M +$795K +58,824 +18%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$6.75M +$4.12M +305,187 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$6.56M +$2.42M +179,092 +152%
IBT
12
International Biotechnology Trust
United Kingdom
$5.47M – – –
GTC
13
Ghost Tree Capital
New York
$4.97M +$3.04M +225,000 New
BC
14
Boxer Capital
California
$4.42M +$2.7M +200,000 New
FCM
15
Farallon Capital Management
California
$4.42M +$2.7M +200,000 New
BC
16
Broadfin Capital
New York
$3.32M +$2.03M +150,000 New
SCM
17
Stonepine Capital Management
Oregon
$3.05M +$1.87M +138,100 New
ACP
18
Acuta Capital Partners
California
$2.85M +$1.74M +128,844 New
Renaissance Technologies
19
Renaissance Technologies
New York
$2.6M +$1.1M +81,621 +228%
MIM
20
Monashee Investment Management
Massachusetts
$1.77M – – –
WCM
21
Wedge Capital Management
North Carolina
$1.49M +$912K +67,460 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.42M +$588K +43,483 +209%
Millennium Management
23
Millennium Management
New York
$1.15M +$526K +38,924 +297%
EI
24
EAM Investors
California
$926K +$566K +41,896 New
BCM
25
Bridgeway Capital Management
Texas
$907K – – –
1
2 3

KALV Hedge Fund Activity: Q3 2018 in Review

48 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2018, worth a combined $278M — up 442% from $51.3M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KALV positions and 3 closed out — a net gain of 22 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Vivo Capital, adding an estimated $14.3M. The largest seller was Stanley-Laman Group, exiting entirely with an estimated $545K sold.

  • 48 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2018, up from 26 in Q2 2018.
  • Funds reported $278M of KalVista Pharmaceuticals stock for Q3 2018, up 442% quarter-over-quarter.
  • 25 funds opened new KalVista Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +22 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $14.3M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2018 was Stanley-Laman Group, an estimated $545K sold.

Based on aggregated 13F filings for Q3 2018.